CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

SHENZHEN, CHINA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need.